KLRK1 and Miyoshi myopathy: A number of preclinical BiKEs (e.g., BCMA × CD16A, BCMA × MICA, BCMA × NKp30, CS1-NKG2D) have demonstrated promising MM-specific cytotoxicity [167,168,169,170].